RNABiochemistryPeer-reviewed journal article
OpenASO: RNA Rescue--designing splice-modulating antisense oligonucleotides through community science
Victor TseiD, Martin Guiterrez, Jill TownleyiD, Jonathan RomanoiD, Jennifer Pearl, Guillermo Chacaltana, Eterna ParticipantsiD, Rhiju DasiD, Jeremy R. SanfordiD, Michael D. StoneiD
Abstract
Splice-modulating antisense oligonucleotides (ASOs) are precision RNA-based drugs that are becoming an established modality to treat human disease. Previously, we reported the discovery of ASOs that target a novel, putative intronic RNA structure to rescue splicing of multiple pathogenic variants of F8 exon 16 that cause hemophilia A. However, the conventional approach to discovering splice-modulating ASOs is both laborious and expensive. Here, we describe an alternative paradigm that integrates data-driven RNA structure prediction and community science to discover splice-modulating ASOs. Using a splicing-deficient pathogenic variant of F8 exon 16 as a model, we show that 25% of the top-scoring molecules designed in the Eterna OpenASO challenge have a statistically significant impact on enhancing exon 16 splicing. Additionally, we show that a distinct combination of ASOs designed by Eterna players can additively enhance the inclusion of the splicing-deficient exon 16 variant. Together, our data suggests that crowdsourcing designs from a community of citizen scientists may accelerate the discovery of splice-modulating ASOs with potential to treat human disease.
- organism: human
- assay: bulk RNA-seq
- research focus: drug response / drug discovery
- approach: deep learning
- approach: benchmark study
- Citations
- 3
- FWCI
- 0.83
- Field percentile
- top 33%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- One-Size-Fits-Many: Antisense oligonucleotides for rescuing splicing mutations in hotspot exons
Chaorui Duan, Stephen Rong, … William Guy Fairbrother·bioRxiv·Dec 7, 2024
- A scalable platform for exon-skipping antisense oligonucleotide therapy development for inborn genetic diseases
Logan Newton, Bushra Haque, … Gregory Costain·medRxiv·Jul 31, 2026
- Deep indel mutagenesis reveals the regulatory and modulatory architecture of alternative exon splicing
Pablo Baeza-Centurión, Belén Miñana, … Juan Valcárcel·Nature CommunicationsPeer-reviewed·Aug 30, 2025
- Rescue of blood coagulation Factor VIII exon-16 mis-splicing by antisense oligonucleotides
Victor Tse, Guillermo Chacaltana, … Jeremy R. Sanford·bioRxiv·Mar 31, 2023
- Deep screening of proximal and distal splicing-regulatory elements in a native sequence context
Yocelyn Recinos, Dmytro Ustianenko, … Chaolin Zhang·bioRxiv·Aug 21, 2023
- Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10kb C-to-T splicing mutation
Yifat S. Oren, Michal Irony‐Tur Sinai, … Batsheva Kerem·Journal of Cystic FibrosisPeer-reviewed·Jul 2, 2021